Every Form 4 that Labcorp Holdings Inc. (LH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow LH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LH filings page.
Labcorp Holdings Inc. executive Jonathan C. Meltzer reported multiple equity transactions. On February 10, 2026, he sold 91 shares of Labcorp common stock in an open-market transaction at $276.79 per share under a pre-arranged Rule 10b5-1 trading plan, leaving him with 2,696.3256 shares held directly.
On the same date, he was granted 1,900 non-qualified stock options with an exercise price of $284.50, vesting in three equal annual installments starting February 10, 2027 and expiring on February 9, 2036. He also received 620 restricted stock units, which vest in three equal annual installments beginning February 10, 2027, bringing his directly held RSUs to 2,937 units, each representing one share of Labcorp common stock.
Labcorp Holdings Inc. executive Kathryn W. Kyle, EVP and Chief Legal Officer, reported new equity awards. On February 10, 2026, she received 2,700 non-qualified stock options with an exercise price of $284.5 per share, granted under the Labcorp 2025 Omnibus Incentive Plan. These options vest in three equal annual installments starting on the grant date and are exercisable until February 9, 2036.
She was also granted 880 Restricted Stock Units (RSUs), each representing one share of common stock. The RSUs vest in three equal annual installments beginning on February 10, 2027. After this grant, she holds a total of 2,480 RSUs directly.
Labcorp Holdings Inc. executive Bryan T. Vaughn reported equity awards granted on February 10, 2026. He received non-qualified stock options on 2,200 shares of common stock at an exercise price of $284.5 per share, vesting in three equal annual installments starting on that grant date and expiring on February 9, 2036.
He was also granted 730 Restricted Stock Units, each representing one share of common stock, which vest in three equal annual installments beginning on February 10, 2027. Following this RSU grant, Vaughn directly holds 4,354 Restricted Stock Units in total.
Labcorp Holdings Inc. chief financial officer Julia Aijun Wang received new equity awards. On February 10, 2026, she was granted 7,100 non-qualified stock options with an exercise price of $284.50 per share and 2,350 restricted stock units.
The options vest in three equal annual installments starting on the grant date and are exercisable until February 9, 2036. The restricted stock units also vest in three equal annual installments beginning on February 10, 2027, with each unit delivering one share of Labcorp common stock.
Labcorp Holdings Inc. reported that SVP and Chief Accounting Officer Peter J. Wilkinson acquired new equity awards on February 10, 2026. He received non-qualified stock options for 1,300 shares of common stock with an exercise price of $284.5 per share, granted under the 2025 Omnibus Incentive Plan. These options vest in three equal annual installments starting on that grant date and expire on February 9, 2036.
Wilkinson was also granted 440 Restricted Stock Units, each representing one share of common stock, vesting in three equal annual installments beginning on February 10, 2027. Following this grant, he holds 2,664 Restricted Stock Units in total, all reported as directly owned.
Labcorp Holdings Inc. executive Akinbolade Oyegunwa reported new equity awards. On 02/10/2026, the EVP, CIO & CTO acquired 2,400 non-qualified stock options with an exercise price of $284.5 per share under the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan.
The options vest in three equal annual installments beginning on 02/10/2026 and are exercisable until 02/09/2036. On the same date, Oyegunwa also received 810 Restricted Stock Units, each representing one share of common stock, which will vest in three equal annual installments beginning on February 10, 2027. Following this grant, Oyegunwa holds 2,420 Restricted Stock Units in total.
Labcorp Holdings Inc. executive Amy B. Summy, EVP and Chief Marketing Officer, reported new equity awards on February 10, 2026. She received 1,900 non-qualified stock options with an exercise price of $284.50 per share under the 2025 Omnibus Incentive Plan. These options vest in three equal annual installments starting on the grant date and cover 1,900 shares of common stock.
She also acquired 620 Restricted Stock Units (RSUs), each representing one share of common stock, which vest in three equal annual installments beginning on February 10, 2027. Following this grant, she directly holds 1,534 RSUs in total. The filing reflects routine compensation-related awards rather than open-market purchases or sales.
Labcorp Holdings Inc. executive Anita Z. Graham, EVP and Chief Human Resources Officer, reported equity awards granted on February 10, 2026. She received non-qualified stock options for 4,100 shares of common stock with an exercise price of $284.5 per share, vesting in three equal annual installments beginning that date. She was also granted 1,360 Restricted Stock Units, each representing one share of common stock, which vest in three equal annual installments beginning on February 10, 2027. Following this award, she holds 2,757 Restricted Stock Units in total.
Labcorp Holdings Inc. executive Megan D. Bailey reported equity awards received on February 10, 2026. She was granted 3,300 non-qualified stock options with a $284.5 exercise price under the 2025 Omnibus Incentive Plan, vesting in three equal annual installments starting on that grant date.
She was also granted 1,100 Restricted Stock Units, each representing one share of common stock, which vest in three equal annual installments beginning on February 10, 2027. After this grant, she directly holds 3,300 stock options and 3,230 Restricted Stock Units.
Labcorp Holdings Inc. executive Brian J. Caveney, EVP, President of Enterprise Diagnostics, CMO and CSO, received new equity awards. On February 10, 2026 he was granted 6,100 non-qualified stock options with an exercise price of $284.5 per share, vesting in three equal annual installments beginning February 10, 2027.
He was also granted 2,020 Restricted Stock Units (RSUs), each representing one share of common stock, which vest in three equal annual installments starting February 10, 2027. After this grant, he holds 6,100 options and 4,910 RSUs directly.
Labcorp Holdings Inc. director Garheng Kong reported an equity award of restricted stock units. On February 10, 2026, Kong acquired 773 Restricted Stock Units, each representing the right to receive one share of Labcorp common stock. These units vest fully on February 10, 2027.
Following this grant, Kong beneficially owns 1,670 Restricted Stock Units, held directly. This filing reflects a stock-based compensation award rather than an open-market purchase or sale.
Labcorp Holdings Inc. director Paul Rothman reported an equity award in the form of Restricted Stock Units. On February 10, 2026, he acquired 733 Restricted Stock Units as a grant, each representing the right to receive one share of Labcorp common stock if vesting conditions are met.
These Restricted Stock Units vest fully on February 10, 2027. Following this grant, Rothman beneficially holds a total of 1,670 Restricted Stock Units in a direct ownership capacity, aligning his compensation more closely with the company’s future share performance.
Labcorp Holdings Inc. director John H. Sampson received an equity award of 773 restricted stock units on February 10, 2026. The Form 4 reports this as an acquisition of derivative securities at a price of $0 per unit, held as direct beneficial ownership.
Each restricted stock unit represents the contingent right to receive one share of Labcorp common stock. The 773 restricted stock units vest fully on February 10, 2027, and the filing shows 773 derivative securities beneficially owned following the reported transaction.
Labcorp Holdings Inc. director Kathryn E. Wengel received an equity award of 773 Restricted Stock Units on February 10, 2026. The award was reported at a price of $0 per unit as a grant, not an open-market purchase.
Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp common stock, and the units vest fully on February 10, 2027. Following this grant, Wengel beneficially holds a total of 1,670 Restricted Stock Units directly.
Labcorp Holdings Inc. director Richelle P. Parham received a new equity award in the form of restricted stock units. On February 10, 2026, she acquired 773 Restricted Stock Units, each representing the right to receive one share of Labcorp common stock, at no cash cost.
The Restricted Stock Units vest fully on February 10, 2027, meaning the shares will be delivered if the vesting conditions are satisfied. After this grant, Parham beneficially holds a total of 1,670 Restricted Stock Units directly.
Labcorp Holdings Inc. director Peter M. Neupert reported an equity award under a company plan. On February 10, 2026, he received 773 Restricted Stock Units (RSUs) at a price of $0 per unit. Each RSU represents the right to receive one share of Labcorp common stock.
The RSUs vest fully on February 10, 2027, meaning he will receive the underlying shares if vesting conditions are met. After this grant, Neupert beneficially owns 1,670 RSUs in total, all held as direct ownership.
Labcorp Holdings Inc. director Kirsten M. Kliphouse acquired 773 Restricted Stock Units on February 10, 2026 as an equity grant. Each unit represents the right to receive one share of Labcorp common stock. These units vest in full on February 10, 2027, subject to the award terms.
Following this grant, Kliphouse beneficially owns a total of 1,670 Restricted Stock Units, all held as direct ownership. The transaction was reported as a grant, award, or other acquisition at a price of $0 per unit.
Labcorp Holdings Inc. director Jeffrey A. Davis received an equity grant of 773 Restricted Stock Units on February 10, 2026. Each unit represents the right to receive one share of Labcorp common stock. The Restricted Stock Units vest fully on February 10, 2027.
After this award, Davis beneficially owns a total of 1,670 Restricted Stock Units in Labcorp through direct ownership, reflecting his aggregate RSU holdings as reported.
Labcorp Holdings Inc. director Victor Bulto Carulla was granted 773 Restricted Stock Units (RSUs) on February 10, 2026, as reported in a Form 4 insider filing. Each RSU represents the contingent right to receive one share of Labcorp common stock.
The RSUs vest fully on February 10, 2027, meaning the director must remain eligible through that date to receive the underlying shares. Following this grant, the director beneficially owns 909 RSUs in total, all held in a direct ownership capacity.
Labcorp Holdings Inc. director Kerrii B. Anderson received an equity award of 773 Restricted Stock Units on February 10, 2026. The award was reported as an acquisition of derivative securities at a price of $0 per unit under a standard grant or award transaction code.
Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. common stock. These units vest fully on February 10, 2027. Following this grant, Anderson beneficially owns a total of 1,670 Restricted Stock Units, all held as direct ownership.
Labcorp Holdings Inc. (LH) Chief Financial Officer and EVP Julia Aijun Wang reported equity compensation activity on February 6, 2026. 893 Restricted Stock Units vested and converted into 893 shares of common stock, consistent with a multi-year vesting schedule that began on February 6, 2025.
To cover tax withholding obligations, 254 of these shares were withheld at a price of $277.2 per share, leaving 1,202.239 shares of common stock beneficially owned directly after the transactions. Wang also directly holds 3,474 Restricted Stock Units, each representing the right to receive one share of Labcorp common stock.
Labcorp Holdings Inc. executive Brian J. Caveney, EVP, President of Enterprise Diagnostics, CMO and CSO, reported multiple equity transactions tied to vested restricted stock units. On February 6 and 7, 2026, a total of 670, 517 and 111 restricted stock units converted into the same number of Labcorp common shares at an exercise price of $0 per share. Shares were then withheld on February 6 and 9, 2026 to cover tax obligations, including 209 shares at $277.2 per share and 148 and 32 shares at $274.01 per share. After these transactions, Caveney directly owned 31,077.9234 Labcorp common shares, and 2,890 restricted stock units remained outstanding.
Labcorp Holdings Inc. executive Akinbolade Oyegunwa, EVP, CIO & CTO, reported routine equity compensation activity. On February 6 and 7, 2026, restricted stock units (RSUs) covering 180 and 149 shares of common stock, respectively, were converted into Labcorp common shares.
To cover tax withholding obligations, a total of 112 common shares were withheld, at prices of $277.2 and $274.01 per share. Following these transactions, Oyegunwa directly held 3,944.253 shares of common stock and 1,610 RSUs, each RSU representing the right to receive one share of common stock as they vest over the disclosed schedules.
Labcorp Holdings Inc. President & CEO Adam H. Schechter reported multiple equity transactions. On February 6 and 7, 2026, he exercised restricted stock units, converting 4,460 and 3,249 RSUs into an equal number of common shares at an exercise price of $0 per share. Related grants vest in three equal annual installments beginning on February 6, 2025 and February 7, 2024.
To cover tax withholding, Schechter had 1,315 shares withheld at $277.20 on February 6, 2026 and 1,352 shares withheld at $274.01 on February 9, 2026. After these transactions, he directly held 92,616 shares of common stock and 18,679 restricted stock units.
Labcorp Holdings Inc. executive Peter J. Wilkinson, SVP and Chief Accounting Officer, reported multiple equity award transactions. On February 6 and 7, 2026, Restricted Stock Units (RSUs) vested and were converted into 133 and 134 shares of common stock, respectively, each RSU representing one share.
To cover tax withholding obligations related to these vestings, 45 shares at $277.20 per share on February 6 and 46 shares at $274.01 per share on February 9 were withheld. After these transactions, Wilkinson directly held 2,028.2194 shares of Labcorp common stock and 2,224 RSUs in total.
Labcorp Holdings Inc. executive Mark S. Schroeder, EVP, President Diagnostics & COO, reported multiple equity compensation events in early February 2026. On February 6–7, 2026, a total of 1,424 Restricted Stock Units converted into an equal number of common shares at a stated price of $0 per share, reflecting vesting of prior awards.
To cover tax withholding obligations, the company withheld 239 common shares at $277.2 on February 6 and 166 and 53 common shares at $274.01 on February 9, as indicated by transaction code “F” and the tax footnote. After these transactions, Schroeder directly held 5,926.1426 common shares and 3,164 Restricted Stock Units, each RSU representing the contingent right to receive one Labcorp common share.
Labcorp Holdings Inc. executive Sandra D. van der Vaart, EVP Corporate Affairs, reported multiple stock transactions involving restricted stock units (RSUs) and related tax withholding. On February 6, 2026, 387 RSUs were converted into the same number of Labcorp common shares at an exercise price of $0, and 101 shares were disposed of at $277.20 per share to cover tax withholding, leaving 2,589.4864 common shares directly owned. On February 7, 2026, a further 353 RSUs were converted into common stock at $0, increasing direct ownership to 2,942.4864 shares. On February 9, 2026, 93 shares were disposed of at $274.01 per share for tax withholding, with 2,849.4864 common shares held directly afterward. The filing shows 1,870 RSUs held after the February 6 transaction and 1,517 RSUs after the February 7 transaction, each RSU representing the right to receive one Labcorp common share. The share totals include 29.8173 shares acquired under the company’s 2025 Employee Stock Purchase Plan.
Labcorp Holdings Inc. executive Bryan T. Vaughn reported routine equity compensation activity. As EVP, Diagnostics, he exercised restricted stock units (RSUs) into common stock on February 6 and 7, 2026, with corresponding increases in directly owned shares.
On February 6 and 9, 2026, small blocks of common stock were withheld and disposed of under code "F" at prices of $277.2 and $274.01 per share to satisfy tax withholding obligations, as noted in the footnotes. Following these transactions, he directly owned about 5,382.5702 shares of Labcorp common stock and 3,624 RSUs, which each represent the right to receive one share upon settlement.
Labcorp Holdings Inc. executive Jonathan C. Meltzer, EVP of Operations, reported multiple equity transactions in early February 2026. On February 6 and 7, 2026, a total of 530 Restricted Stock Units (RSUs) were converted to the same number of Labcorp common shares at an exercise price of $0. Some of the resulting shares were withheld to cover tax obligations.
On February 9, 2026, Meltzer sold 88 shares of common stock at $275.53 per share pursuant to a Rule 10b5-1 trading plan, and additional shares were withheld for taxes. After these transactions, he directly holds 2,787.3256 Labcorp common shares and 2,317 RSUs, each RSU representing the contingent right to receive one share of common stock.
Labcorp Holdings Inc. executive Kathryn W. Kyle, EVP and Chief Legal Officer, reported routine equity transactions involving restricted stock units (RSUs) and related common stock. On February 6 and 7, 2026, RSUs covering 180 and 178 shares, respectively, were converted into Labcorp common stock at an exercise price of $0 per share.
To cover tax withholding obligations tied to these vestings, 61 shares were withheld at $277.20 per share on February 6 and another 61 shares at $274.01 per share on February 9, as indicated by transaction code F. After these transactions, Kyle directly owned 3,288.4574 shares of common stock and held 1,600 RSUs, which each represent the right to receive one share of Labcorp common stock.
Labcorp Holdings Inc. executive Anita Z. Graham, EVP and CHRO, reported multiple equity transactions involving company stock and restricted stock units (RSUs). On February 6 and 7, 2026, RSUs converted into common stock (coded "M"), reflecting scheduled vesting from prior grants.
To cover tax withholding obligations, a portion of the newly delivered shares was withheld and disposed of (coded "F") at prices of $277.20 and $274.01 per share, rather than sold in an open-market trade. Each RSU represents the right to receive one share of common stock, and the filing notes grants vesting in three equal annual installments beginning on February 6, 2025 and February 7, 2024.
Following these transactions, Graham directly holds 1,213 shares of Labcorp common stock, as well as outstanding RSU balances as reflected in the derivative securities table.
Labcorp Holdings Inc. executive Amy B. Summy, EVP and Chief Marketing Officer, reported multiple equity transactions. On February 6 and 7, 2026, restricted stock units (RSUs) converted into 223 and 222 shares of common stock, respectively, at an exercise price of $0.
To cover tax withholding obligations, 92 shares of common stock at $277.2 per share on February 6 and 80 shares at $274.01 per share on February 9 were withheld and disposed of. Following these transactions, she directly beneficially owned 5,574.5 shares of common stock and continued to hold RSUs, including 1,136 and 914 units from separate awards.
Labcorp Holdings Inc. executive Megan D. Bailey reported routine equity compensation activity involving restricted stock units (RSUs) and related common stock transactions. On February 6 and 7, 2026, RSUs converted into 180, 222, and 67 shares of common stock at an exercise price of $0, reflecting vesting of prior equity awards.
To cover tax withholding obligations tied to these vestings, 72 shares were withheld at $277.20 on February 6, 2026, and 85 and 23 shares were withheld at $274.01 on February 9, 2026. After these transactions, Bailey directly held 3,883 shares of Labcorp common stock and 2,130 RSUs, which each represent a contingent right to receive one share of common stock.
Labcorp Holdings Inc. director Victor Bulto Carulla reported a new equity award in the form of restricted stock units. On December 1, 2025, he received 136 Restricted Stock Units, each representing the right to receive one share of Labcorp Holdings Inc. common stock. The award was reported as directly owned.
The Restricted Stock Units are scheduled to vest fully on December 1, 2026, meaning the shares underlying the award become deliverable on that date, subject to the award’s usual conditions. This filing is a routine disclosure of director equity compensation and does not involve any open‑market purchase or sale of shares.
Labcorp (LH) reported an insider transaction by President & CEO and Director Adam H. Schechter. On 11/11/2025, he sold 5,745 shares of common stock at $262.75 per share, as disclosed on Form 4.
The transaction was made pursuant to a Rule 10b5-1 trading plan. Following the sale, Schechter beneficially owns 87,574 shares, held directly.
Labcorp (LH) Form 4: EVP, President of Central Labs & International Megan D. Bailey reported equity transactions. On 11/01/2025, 370 shares of Common Stock were acquired (code M) from Restricted Stock Units. On 11/03/2025, 179 shares were surrendered (code F) at $257.84 to satisfy tax withholding.
Following these transactions, direct ownership stands at 3,594 Common Stock shares. Derivative holdings include 2,599 Restricted Stock Units that vest in three equal annual installments beginning on November 1, 2025.
Labcorp (LH) reported an insider equity update by EVP, CIO & CTO Akinbolade Oyegunwa. On 11/01/2025, 370 shares of common stock were acquired via the conversion of Restricted Stock Units (code M). On 11/03/2025, 107 shares were withheld to cover taxes at $257.84 per share (code F). Following these transactions, direct holdings are 3,727.253 shares.
The filing notes 1,939 Restricted Stock Units remain outstanding. These RSUs vest in three equal annual installments beginning on November 1, 2025.
Labcorp (LH) reported an insider transaction by Director Richelle P. Parham. On 10/31/2025, she executed a sale (Transaction Code S) of 7,009 shares of common stock at an average price of $254.2835 per share. Following the sale, she beneficially owns 2,469 shares, held directly.
The filing was signed by an attorney-in-fact on 11/04/2025.